Criticism Over Missed Shows, and Jennifer Simard's Disclosure About Uterine Fibroids

At Broadway's "Death Becomes Her" musical, Jennifer Simard's presence was a draw for audiences. But on certain evenings, the stage showed her understudy instead. Some ticket-buyers grew upset, and a few took to social media to ask why the actress was not regularly in the show. Demanding such an accounting from stars is nothing new on Broadway, but in Simard's case the story took a different turn.

Simard did not answer quickly. She completed her treatment, gave her body time to rest, and then came forward. In an interview with PEOPLE—later carried by The Express Tribune and other outlets—she said she had been diagnosed with uterine fibroids. The situation became so complicated that she ultimately required a hysterectomy and an oophorectomy, the removal of her uterus and ovaries. It was this health crisis that forced her to step away from multiple performances.

What exactly are uterine fibroids? They are benign tumors that grow from the muscular layer of the uterus and are found in many women of reproductive age. For some there are no symptoms at all; for others they cause bleeding, pain, or other complications. The type of treatment depends on the size and number of fibroids and the patient's overall condition. In Simard's case, surgery was chosen—and it was the most definitive kind: not only the uterus but the ovaries were removed as well.

In Broadway's structure, a performer's absence is never purely personal; it is tied directly to a production's box office, the workload of understudies, and audience expectations. When a lead suddenly drops out of a major musical, producers must alter plans, understudies must prepare at speed, and ticket-buyers may realize their expectations will not be met. It was exactly this strain that emerged during Simard's absence.

This is where an uncomfortable dimension surfaces. An audience's ticket money and expectations are legitimate. But a performer's body is not public property, and the tendency to demand a public accounting of it is steadily growing. While Simard kept her health crisis private, many read meaning into her silence as they wished. Some assumed disinterest; some assumed there was no serious reason. The real question here is the compulsion to explain a private health decision in public—not merely a missed show.

"Death Becomes Her" is a major Broadway musical that earned several Tony nominations. Simard is not only a performer in this production; she is a Tony-nominated artist whose work in "Disaster!" in 2026 drew praise. In other words, this health crisis arrived at an important point in her career. In such situations, some people pause their careers, while others return anew.

Broadway actually runs a well-organized system for exactly these situations. Understudies, swings, and standbys exist so that a production does not stop when one face is missing. In Simard's case, the system worked; the audience experience was not entirely disrupted. Still, the question remains: why did an actress need to explain her medical information in public?

On a commercial stage like Broadway, a show's success depends on consistent attendance. The same performer stands in the same role week after week, and that continuity builds audience trust. In this structure, the artist's body becomes an asset that sometimes matters more than the artist's own needs. Simard's case is a signal of that reality.

On June 28, the production of "Death Becomes Her" closed. After that, Simard did not vanish from the scene entirely. On September 8, she returned to Broadway, this time in the musical "Schmigadoon!" at the Nederlander Theatre. There she took over a role from Ana Gasteyer. Returning to the stage after six weeks of rest—and taking on new responsibility in a new production—is not merely a story of recovery; it is a story of reconstruction.

Seen medically, the removal of the uterus and ovaries brings hormonal changes that can slow the process of full recovery. Placed in that context, six weeks of rest shows how challenging the return was. Standing on stage means physical exertion, eight shows a week, and giving voice and body in equal measure. For an actress to return under such conditions is not only a matter of courage; it is a matter of planning.

From outside the entertainment industry, many may see this as a personal health story. But inside it lies a professional reality. In a high-pressure art form like Broadway, a performer's body is their core capital. When that capital suddenly comes under threat, a tension arises between personal decision and professional duty. Simard's silence was an expression of that tension—she thought first of her body, then of the explanation.

Behind the audience's criticism there is no lack of empathy, but rather a natural expectation—that the person they paid to see will be on stage. Finding a balance between that expectation and an artist's personal freedom is the real challenge. Simard's case shows that this balance is not always easy, and that a lack of transparency breeds misunderstanding.

On sourcing, this story comes from a first-person account—Simard herself gave the interview to PEOPLE. But much of the information was initially marked as having no source, and The Express Tribune republished the item citing PEOPLE. Second-layer news distribution is normal for personal health information, yet caution toward the original source is necessary.

Behind an artist's absence there is not always disinterest; sometimes it is a reason that is hard to talk about. Before criticising, before judging, it is important to keep that possibility open. This lesson is relevant to both Broadway audiences and producers.

Looking ahead, the question arises: will Broadway build a more empathetic structure for such situations? Or will the pressure for transparency grow further, until an artist must publicly explain even the private matters of their own body? Simard's return offers one answer—artists come back. But on what terms, and at what cost, remains an open question.